Keywords: Mexico, Hepatitis C drugs, Market forecasts, Decision Resources, Merck & Co, Roche, Victrelis, Vertex' Incivek
Hepatitis C drug market in Mexico expected to double to $104 million in 2015
Article | 21 November 2011
The hepatitis C virus (HCV) market in Mexico will nearly double from $56 million in 2010 to $104 million in 2015. According to advisory ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
